Search Result

Results for "

Pgp inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	P-glycoprotein (74) AMPK (1) Amylases (1) Amyloid-β (1) Apoptosis (8) Autophagy (2) Bacterial (1) BCRP (8) Beta-secretase (2) c-Met/HGFR (2) Calcium Channel (9) Cannabinoid Receptor (1) Carbonic Anhydrase (1) CCR (1) CDK (1) Cytochrome P450 (15) Dopamine β-hydroxylase (1) Drug Metabolite (3) Endogenous Metabolite (7) Ferroptosis (1) Glucosidase (1) HCV Protease (1) Hedgehog (2) HIV (6) HIV Protease (6) Isotope-Labeled Compounds (6) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Potassium Channel (1) SARS-CoV (6) TAM Receptor (2) Wee1 (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (77) Cardiovascular Disease (10) Infection (8) Inflammation/Immunology (2) Metabolic Disease (7) Neurological Disease (2)

By Targets:

P-glycoprotein (74)

AMPK (1)

Amylases (1)

Amyloid-β (1)

Apoptosis (8)

Autophagy (2)

Bacterial (1)

BCRP (8)

Beta-secretase (2)

c-Met/HGFR (2)

Calcium Channel (9)

Cannabinoid Receptor (1)

Carbonic Anhydrase (1)

CCR (1)

CDK (1)

Cytochrome P450 (15)

Dopamine β-hydroxylase (1)

Drug Metabolite (3)

Endogenous Metabolite (7)

Ferroptosis (1)

Glucosidase (1)

HCV Protease (1)

Hedgehog (2)

HIV (6)

HIV Protease (6)

Isotope-Labeled Compounds (6)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Potassium Channel (1)

SARS-CoV (6)

TAM Receptor (2)

Wee1 (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (77)

Cardiovascular Disease (10)

Infection (8)

Inflammation/Immunology (2)

Metabolic Disease (7)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144366

P-gp inhibitor 3	P-glycoprotein	Cancer
P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .

HY-155032

P-gp inhibitor 15	P-glycoprotein	Cancer
P-gp inhibitor 15 (compound 7a) is a nonsubstrate inhibitor of P-glycoprotein (Pgp). P-gp inhibitor 15 inhibits Pgp-ATPase activity，and interfers Pgp-mediated Rhodamine123 efflux. P-gp inhibitor 15 also enhances the inhibitory efficacy of Paclitaxel (HY-B0015)，inhibits tumor progress in nude mice KBV xenograft tumors model .

HY-157483

P-gp inhibitor 18	P-glycoprotein	Cancer
P-gp inhibitor 18 (compound 6G) is a potent inhibitor of *P-gp. P-gp* inhibitor 18 inhibits rhodamine 123 efflux in the P-gp overexpressed leukemia cells, K562/Dox .

HY-161260

P-gp inhibitor 20	P-glycoprotein	Cancer
P-gp inhibitor 20 (compound H27) is a low cytotoxicity P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 20 inhibits the efflux function of P-gp in a dose-dependent manner (without affecting the expression of P-gp), thereby reversing the multidrug resistance (MDR) of MCF-7/ADR cells, with an IC₅₀ value of 46.6 nM. P-gp inhibitor 20 can be used for cancer research .

HY-162040

P-gp inhibitor 17	P-glycoprotein	Cancer
P-gp inhibitor 17 (compound 2g) is a *P-gp* inhibitor directly interacted with the transmembrane domain of *P-gp. P-gp* inhibitor 17 can be used for P-gp-mediated multidrug-resistant in tumor cells study .

HY-149981

P-gp inhibitor 13	P-glycoprotein	Cancer
P-gp inhibitor 13 is a *P-gp* inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .

HY-N144114

P-gp inhibitor 2	P-glycoprotein	Cancer
P-gp inhibitor 2 is a potent *P-gp* inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-149813

P-gp inhibitor 14	P-glycoprotein	Cancer
P-gp inhibitor 14 (Compound 8a) is a high affinity *P-gp* inhibitor. P-gp inhibitor 14 reverses P-gp-mediated multidrug resistance (EC₅₀=48.74 nM). P-gp inhibitor 14 has a weak inhibitory effect on CYP3A4 activity .

HY-162447

P-gp inhibitor 22	P-glycoprotein Apoptosis	Cancer
P-gp inhibitor 22 is a P-glycoprotein (P-gp) inhibitor that effectively inhibits P-pg and efflux function. P-gp inhibitor 22 induces apoptosis and accumulation of MCF-7/ADR cells processed in the S phase .

HY-158435

P-gp inhibitor 23	P-glycoprotein Cytochrome P450	Cancer
P-gp inhibitor 23 (compound 14F) is a potent inhibitor of *P-gp* and CYP3A4, with the EC₅₀ and IC₅₀ of 28 nM and 223 nM, respectively .

HY-157330

P-gp inhibitor 16	P-glycoprotein Apoptosis	Cancer
P-gp inhibitor 16 (compound 14) is a p-glycoprotein inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .

HY-150565

P-gp inhibitor 5	P-glycoprotein	Cancer
P-gp inhibitor 5 is a potent P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 5 has antiproliferative activity against certain cancer cell lines. P-gp inhibitor 5 is effective in reversing the multidrug resistance (MDR) phenotype in ABCB1/Flp-In ^TM-293 and KBvin cells by restoring their sensitivity to Vincristine (HY-N0488A) and Paclitaxel (HY-B0015) .

HY-157484

P-gp inhibitor 19	P-glycoprotein	Cancer
P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor. P-gp inhibitor 19 can inhibit the efflux of rhodamine 123 (HY-D0816) in P-gp-overexpressing leukemia cells K562/Dox and also restore the sensitivity of DOX-resistant cells .

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-146391

P-gp inhibitor 4	P-glycoprotein	Cancer
P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC₅₀ of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .

HY-101791

P-gp inhibitor 1	P-glycoprotein	Cancer
P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.

HY-119823

PGP-4008	P-glycoprotein	Cancer
PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin .

HY-161645

P-gp modulator-4	P-glycoprotein	Cancer
P-gp modulator-4 (compound 4c) inhibits the efflux function of P-glycoprotein (P-gp). P-gp modulator-4 shows multidrug resistance (MDR) in cancer reversal activity (IC₅₀ of Paclitaxel (HY-B0015) = 8.80, reversal fold = 211.8) .

HY-19626

NSC23925	P-glycoprotein	Cancer
NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor.

HY-162369

PID-9	P-glycoprotein	Cancer
PID-9 is a P-glycoprotein inhibitor. PID-9 has multidrug resistance (MDR) reversal activity (IC₅₀ = 0.1338 μM) and low toxicity. PID-9 inhibits the transport function of P-gp without downregulating P-gp expression .

HY-10550A

Tariquidar methanesulfonate, hydrate Maximum Cited Publications 47 Publications Verification XR9576 methanesulfonate, hydrate	P-glycoprotein	Cancer
Tariquidar methanesulfonate, hydrate (XR9576 methanesulfonate, hydrate) is a potent and specific inhibitor of P-glycoprotein (P-gp) with a K_d of 5.1 nM.

HY-149360

P-gb-IN-1	P-glycoprotein	Cancer
P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum P-glycoprotein (P-gp) inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells .

HY-144393

P-gp/BCRP-IN-1	BCRP	Cancer
P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of *P-gp* and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel) .

HY-149277

FM04	P-glycoprotein	Cancer
FM04 is a potent P-glycoprotein (P-gp) inhibitor (EC₅₀=83 nM). FM04 inhibits P-gp in 2 mechanism: (1)FM04 binds to Q1193, followed by interacting with the functionally critical residues H1195 and T1226; or (2)FM04 binds to I1115 (a functionally critical residue itself), disrupting the R262-Q1081-Q1118 interaction pocket and uncoupling ICL2-NBD2 interaction and thereby inhibiting P-gp .

HY-10550

Tariquidar Maximum Cited Publications 47 Publications Verification XR9576	P-glycoprotein	Cancer
Tariquidar (XR9576) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (K_d=5.1 nM) .

HY-110377

Tariquidar dihydrochloride XR9576 dihydrochloride	P-glycoprotein	Cancer
Tariquidar dihydrochloride (XR9576 dihydrochloride) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (K_d=5.1 nM) .

HY-W009141

1-Monopalmitin Glyceryl palmitate	P-glycoprotein	Cancer
1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-100750

Norverapamil hydrochloride 1 Publications Verification (±)-Norverapamil hydrochloride; D591 hydrochloride	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor .

HY-135328

Norverapamil (±)-Norverapamil; D591	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor .

HY-163204

RhQ-DMB	P-glycoprotein	Cancer
RhQ-DMB is a potent inhibitor of *P-gp*. RhQ-DMB exhibits high affinity and inhibitory activity in yeast strains expressing CmABCB1 .

HY-N1457

Chrysosplenetin	P-glycoprotein Cytochrome P450 Ferroptosis	Metabolic Disease
Chrysosplenetin is one of the polymethoxylated flavonoids in Artemisia annua L. (Compositae) and other several Chinese herbs. Chrysosplenetin inhibits *P-gp* activity and reverses the up-regulated P-gp and MDR1 levels induced by artemisinin (ART). Chrysosplenetin significantly augments the rat plasma level and anti-malarial efficacy of ART, partially due to the uncompetitive inhibition effect of Chrysosplenetin on rat CYP3A .

HY-107643

Reversan CBLC4H10	P-glycoprotein	Cancer
Reversan (CBLC4H10) is a potent and nontoxic multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (Pgp) inhibitor .

HY-N0689

Evodine	P-glycoprotein	Cancer
Evodine, the major limonoid of Evodiae Fuctus, is a potent *P-gp* inhibitor. Evodine has protection against glutamateinduced toxicity by preserving the antioxidant defense system .

HY-N10563

Coleon-U-quinone	P-glycoprotein	Cancer
Coleon-U-quinone is a potent *P-gp* inhibitor. Coleon-U-quinone can inhibit cancer cells viability and sensitize multidrug resistance cancer cells to Doxorubicin (HY-15142A) .

HY-128685

FD 12-9 Ac12Az9	P-glycoprotein BCRP	Cancer
FD 12-9 is a flavonoid dimer, acts as a dual inhibitor of *P-gp* and BCRP, with EC₅₀s of 285 nM and 0.9 nM, respectively. Anti-glioblastoma activity .

HY-N0425

Epoxylathyrol	P-glycoprotein	Cancer
Epoxylathyrol, an epoxylathyrane derivative isolated from the Euphorbia boetica, is a P-glycoprotein (P-gp) inhibitor. Epoxylathyrol is a P-gp-mediated multidrug resistance (MDR) reverser .

HY-13925

PD0166285 4 Publications Verification	Wee1 Apoptosis	Cancer
PD0166285, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC₅₀ values of 24 and 72 nM, respectively. PD0166285 exhibits an IC₅₀ of 3.433 μM for Chk1 .

HY-135328AS

Norverapamil-d7 hydrochloride (±)-Norverapamil-d₇ (hydrochloride); D591-d7 (hydrochloride)	Calcium Channel	Cardiovascular Disease
Norverapamil-d₇ (hydrochloride) is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-135328S

Norverapamil-d7 (±)-Norverapamil-d₇; D591-d₇	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil-d₇ is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-13925A

PD0166285 dihydrochloride	Wee1 Apoptosis	Cancer
PD0166285 dihydrochloride, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC₅₀ values of 24 and 72 nM, respectively. PD0166285 dihydrochloride exhibits an IC₅₀ of 3.433 μM for Chk1 .

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein	Metabolic Disease Cancer
Voacamine, an indole alkaloid, exhibits potent cannabinoid CB1 receptor antagonistic activity . Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells .

HY-10440

Vismodegib 30+ Cited Publications GDC-0449	Hedgehog Autophagy	Cancer
Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC₅₀ of 3 nM. Vismodegib also inhibits *P-gp, ABCG2* with IC₅₀ values of 3.0 μM and 1.4 μM, respectively .

HY-50671

Zosuquidar trihydrochloride 10+ Cited Publications RS 33295-198 trihydrochloride; LY-335979 trihydrochloride	P-glycoprotein	Cancer
Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (K_i=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .

HY-15255

Zosuquidar 10+ Cited Publications RS 33295-198; LY-335979	P-glycoprotein	Cancer
Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (K_i=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .

HY-50879

Elacridar 20+ Cited Publications GF120918; GW0918; GG918; GW120918	P-glycoprotein BCRP	Cancer
Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer .

HY-N6684

Deoxynivalenol 5 Publications Verification Vomitoxin	Others	Metabolic Disease
Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .

HY-19642A

Glesatinib hydrochloride 2 Publications Verification MGCD265 hydrochloride	TAM Receptor c-Met/HGFR	Cancer
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-19642

Glesatinib MGCD265	TAM Receptor c-Met/HGFR	Cancer
Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-113805

MC70	P-glycoprotein	Cancer
MC70 is a potent and non-selective P-glycoprotein (P-gp) inhibitor with an EC₅₀ of 0.69 µM. MC70 is an ABC transporters inhibitor and anticancer agent. MC70 interacts with ABCB1, ABCG2 and ABCC1 .

HY-N4108

Hypophyllanthin	P-glycoprotein	Inflammation/Immunology Cancer
Hypophyllanthin is a major lignan in Phyllanthus spp, with strong anti-inflammatory activity. Hypophyllanthin directly inhibits P-glycoprotein (P-gp) activity and did not interfere with multidrug resistance protein 2 (MRP2) activity .

Cat. No.	Product Name

HY-L011

Membrane Transporter/Ion Channel Compound Library

1,418 compounds

Most of molecules enter or leave cells mainly via membrane transport proteins, which play important roles in several cellular functions, including cell metabolism, ion homeostasis, signal transduction, the recognition process in the immune system, energy transduction, etc. There are three major types of transport proteins, ATP-powered pumps, channel proteins and transporters. Transport proteins such as channels and transporters play important roles in the maintenance of intracellular homeostasis, and mutations in these transport protein genes have been identified in the pathogenesis of a number of hereditary diseases. In the central nervous system, ion channels have been linked to, but not limited to, many diseases such asataxias, paralyses, epilepsies, and deafness. This indicates the roles of ion channels in the initiation and coordination of movement, sensory perception, and encoding and processing of information. Ion channels are a major class of drug targets in drug development.

MCE designs a unique collection of 1,418 smal-molecule modulators that can be used for the research of Ion Channel and Membrane Transporter or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W009141

1-Monopalmitin Glyceryl palmitate	Source classification Plants	P-glycoprotein
1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-N1457

Chrysosplenetin	Flavonols Structural Classification Piscidia erythrina L. Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Compositae Disease Research Fields	P-glycoprotein Cytochrome P450 Ferroptosis
Chrysosplenetin is one of the polymethoxylated flavonoids in Artemisia annua L. (Compositae) and other several Chinese herbs. Chrysosplenetin inhibits *P-gp* activity and reverses the up-regulated P-gp and MDR1 levels induced by artemisinin (ART). Chrysosplenetin significantly augments the rat plasma level and anti-malarial efficacy of ART, partially due to the uncompetitive inhibition effect of Chrysosplenetin on rat CYP3A .

HY-N144114

P-gp inhibitor 2	Classification of Application Fields Disease Research Fields Cancer	P-glycoprotein
P-gp inhibitor 2 is a potent *P-gp* inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-N0689

Evodine	Alkaloids Classification of Application Fields Source classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Quinoline Alkaloids Plants Disease Research Fields Cancer	P-glycoprotein
Evodine, the major limonoid of Evodiae Fuctus, is a potent *P-gp* inhibitor. Evodine has protection against glutamateinduced toxicity by preserving the antioxidant defense system .

HY-N10563

Coleon-U-quinone	Structural Classification Ketones, Aldehydes, Acids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Plants	P-glycoprotein
Coleon-U-quinone is a potent *P-gp* inhibitor. Coleon-U-quinone can inhibit cancer cells viability and sensitize multidrug resistance cancer cells to Doxorubicin (HY-15142A) .

HY-N0425

Epoxylathyrol	Structural Classification Classification of Application Fields Euphorbia boetica Terpenoids Source classification Diterpenoids Euphorbiaceae Plants Disease Research Fields Cancer	P-glycoprotein
Epoxylathyrol, an epoxylathyrane derivative isolated from the Euphorbia boetica, is a P-glycoprotein (P-gp) inhibitor. Epoxylathyrol is a P-gp-mediated multidrug resistance (MDR) reverser .

HY-N6932

Voacamine	Alkaloids Structural Classification other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields Indole Alkaloids	Cannabinoid Receptor P-glycoprotein
Voacamine, an indole alkaloid, exhibits potent cannabinoid CB1 receptor antagonistic activity . Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells .

HY-N6684

Deoxynivalenol 5 Publications Verification Vomitoxin	Structural Classification Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Metabolic Disease Disease Research Fields	Others
Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .

HY-N4108

Hypophyllanthin	Phyllanthus urinaria Linn. Structural Classification Classification of Application Fields Source classification Lignans Euphorbiaceae Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields	P-glycoprotein
Hypophyllanthin is a major lignan in Phyllanthus spp, with strong anti-inflammatory activity. Hypophyllanthin directly inhibits P-glycoprotein (P-gp) activity and did not interfere with multidrug resistance protein 2 (MRP2) activity .

HY-N6748

Roquefortine C 1 Publications Verification	Infection Microorganisms Classification of Application Fields Cyclopeptides Source classification Disease Research Fields	P-glycoprotein Cytochrome P450 Bacterial Endogenous Metabolite
Roquefortine C, a fungal cyclopeptide isolated from Penicillium roquefortii, activates *P-gp* and also inhibits P450-3A and other haemoproteins. Roquefortine C has bacteriostatic activities against Gram-positive bacteria .

HY-N10564

8α,9α-Epoxycoleon-U-quinone	Structural Classification Ketones, Aldehydes, Acids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Plants	P-glycoprotein
8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits *P-gp* activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .

HY-17367

Atazanavir Maximum Cited Publications 11 Publications Verification BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-17367A

Atazanavir sulfate Maximum Cited Publications 11 Publications Verification BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-N3028

Taccalonolide B	Structural Classification Classification of Application Fields Source classification Schizocapsa plantaginea Hance Plants Disease Research Fields Taccaceae Steroids Cancer	Microtubule/Tubulin
Taccalonolide B is microtubule stabilizer isolated from Tacca plantaginea, with antitumor activity. Taccalonolide B is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug-resistance protein (MRP7). Taccalonolide B inhibits growth of SK-OV-3 cells with an IC₅₀ of 208 nM .

HY-17367R

Atazanavir (Standard)	Structural Classification Alkaloids Source classification Pyridine Alkaloids Endogenous metabolite	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

Cat. No.	Product Name	Chemical Structure

HY-135328AS

Norverapamil-d7 hydrochloride
Norverapamil-d₇ (hydrochloride) is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-A0064S

Verapamil-d3 hydrochloride

Verapamil-d₃ (hydrochloride) is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].

HY-135328S

Norverapamil-d7
Norverapamil-d₇ is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-14275S1

Verapamil-d7
Verapamil-d₇ is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-17367S3

Atazanavir-d5

Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9

Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S4

Atazanavir-d6

Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-A0064S1

Verapamil-d6 hydrochloride

Verapamil-d₆ (CP-16533-1-d₆) hydrochloride is the deuterium labled Verapamil (hydrochloride) (HY-A0064). Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks